The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | NP30179: Glofitamab monotherapy in R/R NHL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides updates from the Phase I/II NP30179 trial (NCT03075696) of single-agent glofitamab, a CD20xCD3 T-cell-engaging bispecific antibody, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). In the dose-escalation trial, glofitamab produced durable responses, and further data are yet to be presented. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
